HeartBeam to Host Virtual Roadshow Webinar on Tuesday September 20, 2022 at 4:30 p.m. Eastern Time

Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has announced a virtual roadshow webinar on September 20, 2022, at 4:30 p.m. ET. During this event, a new video showcasing the HeartBeam AIMIGo technology for heart attack detection will be unveiled. While the AIMI and AIMIGo technologies are pending FDA clearance, they aim to enhance heart attack detection outside of medical settings. The webinar will feature CEO Branislav Vajdic and other executives discussing the company’s milestones and 510(k) application progress. Access the webinar via the provided link.

Unveils New Video Featuring the HeartBeam AIMI™ and AIMIGo™ Technology

SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced that it will host a virtual roadshow webinar on Tuesday September 20, 2022, at 4:30 p.m. Eastern Time.

(Graphic: Business Wire)

During the webinar, a new video showcasing the HeartBeam AIMIGo platform technology for use in heart attack detection will be unveiled. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies.

The video is available in the company’s investor relations section here.

The video takes viewers behind the scenes for a featured look at the HeartBeam AIMIGo technology, a medical grade solution with a 510(K) regulatory pathway that the company expects to submit to FDA for clearance by the end of the year. Once cleared, for the first time outside of a medical setting, the Company believes that AIMIGo can enable patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be initiated, if needed. The goal of HeartBeam’s technology is to offer more accurate heart attack detection to triage patients and expedite treatment and save healthcare dollars.

HeartBeam’s CEO and founder Branislav Vajdic, PhD, CFO Rick Brounstein, and Chief Business Officer Jon Hunt, PhD, will host the virtual roadshow webinar, during which they will review recent announcements, including its 510(k) application to the FDA for its HeartBeam AIMI™ platform technology, ongoing initiatives and discuss key 2022 and 2023 milestones. The webinar will be accompanied by a presentation and followed by a question-and-answer session from webcast viewers, which can be accessed via the webcast link.

To access the webinar, please use the following information:

Date:			Tuesday September 20, 2022
Time:			4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-in:			1-877-704-4453
International Dial-in:			1-201-389-0920
Conference Code:			13732771
Webcast:			https://viavid.webcasts.com/starthere.jsp?ei=1569585&tp_key=156ad0b0f4

A telephone replay will be available approximately two hours after the call and will run through December 20, 2022, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 13732771. The replay can also be viewed through the webinar webcast link above and the presentation utilized during the call will be available in the company’s investor relations section here.

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack. For more information, visit www.heartbeam.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our in our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005339/en/

Media and Investor Relations Contact:

Chris Tyson

Executive Vice President

MZ North America

Direct: 949-491-8235

BEAT@mzgroup.us

www.mzgroup.us

Source: HeartBeam, Inc.

FAQ

What is the date and time of the HeartBeam webinar?

The HeartBeam webinar is scheduled for September 20, 2022, at 4:30 p.m. ET.

What technology will HeartBeam unveil during the webinar?

HeartBeam will unveil the HeartBeam AIMIGo technology for heart attack detection during the webinar.

Is HeartBeam's AIMI technology FDA approved?

No, the HeartBeam AIMI and AIMIGo technologies have not yet been cleared by the FDA.

What is the purpose of HeartBeam's AIMIGo technology?

The AIMIGo technology aims to enable quick and easy heart attack detection outside of medical settings.

Who will be hosting the HeartBeam webinar?

The webinar will be hosted by HeartBeam's CEO Branislav Vajdic, CFO Rick Brounstein, and Chief Business Officer Jon Hunt.

How can I access the HeartBeam webinar?

You can access the HeartBeam webinar through the provided webcast link.